首页> 美国卫生研究院文献>PLoS Clinical Trials >Genome-Wide MicroRNA Expression Analysis of Clear Cell Renal Cell Carcinoma by Next Generation Deep Sequencing
【2h】

Genome-Wide MicroRNA Expression Analysis of Clear Cell Renal Cell Carcinoma by Next Generation Deep Sequencing

机译:下一代深度测序在透明细胞肾细胞癌基因组范围内的MicroRNA表达分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

MicroRNAs (miRNAs), non-coding RNAs regulating gene expression, are frequently aberrantly expressed in human cancers. Next-generation deep sequencing technology enables genome-wide expression profiling of known miRNAs and discovery of novel miRNAs at unprecedented quantitative and qualitative accuracy. Deep sequencing was performed on 11 fresh frozen clear cell renal cell carcinoma (ccRCC) and adjacent non-tumoral renal cortex (NRC) pairs, 11 additional frozen ccRCC tissues, and 2 ccRCC cell lines (n = 35). The 22 ccRCCs patients belonged to 3 prognostic sub-groups, i.e. those without disease recurrence, with recurrence and with metastatic disease at diagnosis. Thirty-two consecutive samples (16 ccRCC/NRC pairs) were used for stem-loop PCR validation. Novel miRNAs were predicted using 2 distinct bioinformatic pipelines. In total, 463 known miRNAs (expression frequency 1–150,000/million) were identified. We found that 100 miRNA were significantly differentially expressed between ccRCC and NRC. Differential expression of 5 miRNAs was confirmed by stem-loop PCR in the 32 ccRCC/NRC samples. With respect to RCC subgroups, 5 miRNAs discriminated between non-recurrent versus recurrent and metastatic disease, whereas 12 uniquely distinguished non-recurrent versus metastatic disease. Blocking overexpressed miR-210 or miR-27a in cell line SKCR-7 by transfecting specific antagomirs did not result in significant changes in proliferation or apoptosis. Twenty-three previously unknown miRNAs were predicted in silico. Quantitative genome-wide miRNA profiling accurately separated ccRCC from (benign) NRC. Individual differentially expressed miRNAs may potentially serve as diagnostic or prognostic markers or future therapeutic targets in ccRCC. The biological relevance of candidate novel miRNAs is unknown at present.
机译:微小RNA(miRNA)是调节基因表达的非编码RNA,通常在人类癌症中异常表达。下一代深度测序技术可实现已知miRNA的全基因组表达谱分析,并以前所未有的定量和定性准确性发现新型miRNA。对11个新鲜的冷冻透明细胞肾细胞癌(ccRCC)和相邻的非肿瘤性肾皮质(NRC)对,另外11个冷冻的ccRCC组织和2个ccRCC细胞系进行了深度测序(n = 35)。 22例ccRCC患者属于3个预后亚组,即无疾病复发,复发和诊断时有转移性疾病的亚组。使用32个连续样本(16个ccRCC / NRC对)进行茎环PCR验证。使用2种不同的生物信息流水线预测了新型miRNA。总共鉴定出463个已知的miRNA(表达频率1-150,000 /百万)。我们发现ccRCC和NRC之间有100个miRNA显着差异表达。通过32个ccRCC / NRC样品中的茎环PCR确认了5种miRNA的差异表达。关于RCC亚组,有5种miRNA区分了非复发性与复发性和转移性疾病,而12种独特地区分了非复发性与转移性疾病。通过转染特定的拮抗剂来阻断SKCR-7细胞系中过表达的miR-210或miR-27a不会导致增殖或凋亡的显着变化。在计算机上预测了23种先前未知的miRNA。全基因组的定量miRNA分析可将ccRCC与(良性)NRC准确分开。单个差异表达的miRNA可能在ccRCC中充当诊断或预后标志物或未来的治疗靶标。目前尚不清楚候选新型miRNA的生物学相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号